Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications

被引:23
|
作者
Kumar, Naresh [1 ]
Garg, Ankit [2 ]
Bhatt, Deepak L. [3 ,4 ]
Sabongui, Sandra [5 ]
Gupta, Naveen [5 ]
Chaudhry, Sundeep [6 ]
Arena, Ross [7 ]
Verma, Subodh [5 ]
机构
[1] Whitby Cardiovasc Inst, Res Div, Whitby, ON L1R 3J7, Canada
[2] Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada
[3] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON M5B 1W8, Canada
[6] MET TEST, Div Res & Dev, Atlanta, GA 30328 USA
[7] Univ Illinois, Dept Phys Therapy, Chicago, IL 60612 USA
关键词
diabetes; SGLT2; inhibitor; heart function; heart failure; cardiorespiratory fitness; HEART-FAILURE; INHIBITION;
D O I
10.1139/cjpp-2018-0359
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to prevent heart failure and reduce cardiovascular death in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Whether or not SGLT2 inhibitors improve indices of cardiorespiratory fitness (CRF), an independent predictor of mortality in patients with CVD, remains unknown. We evaluated the effects of empagliflozin on indices of CRF in patients with T2DM. Twenty patients with T2DM received either empagliflozin 10 mg or usual care. Baseline and 3- to 6-month post-treatment measurements of CRF were evaluated using cardiopulmonary exercise testing on a cycle ergometer. Treatment with empagliflozin led to an increased peak oxygen consumption (VO2), reduction in VE/VCO2 slope, and improvement in heart rate recovery. Our results suggest that SGLT2 inhibitors may improve markers of CRF in patients with T2DM. This may help provide important clues into the mechanism of benefit of SGLT2 inhibitors in clinical trials and provide a translational framework for the ongoing large studies of SGLT2 inhibitors in the treatment of heart failure.
引用
收藏
页码:1184 / 1187
页数:4
相关论文
共 50 条
  • [31] Empagliflozin: A Review in Type 2 Diabetes
    James E. Frampton
    Drugs, 2018, 78 : 1037 - 1048
  • [32] Empagliflozin for the treatment of Type 2 diabetes
    Komala, Muralikrishna Gangadharan
    Mather, Amanda
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (03) : 271 - 279
  • [33] Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes
    Jahn, Linda A.
    Hartline, Lee M.
    Nguyen, Thi
    Aylor, Kevin
    Horton, William B.
    Liu, Zhenqi
    Barrett, Eugene J.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2024, 326 (03): : E258 - E267
  • [34] Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
    Hammoudi, Nadjib
    Jeong, Dongtak
    Singh, Rajvir
    Farhat, Ahmed
    Komajda, Michel
    Mayoux, Eric
    Hajjar, Roger
    Lebeche, Djamel
    CARDIOVASCULAR DRUGS AND THERAPY, 2017, 31 (03) : 233 - 246
  • [35] Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes
    Jung, Susanne
    Bosch, Agnes
    Kannenkeril, Dennis
    Karg, Marina, V
    Striepe, Kristina
    Bramlage, Peter
    Ott, Christian
    Schmieder, Roland E.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 364 - 371
  • [36] Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
    Nadjib Hammoudi
    Dongtak Jeong
    Rajvir Singh
    Ahmed Farhat
    Michel Komajda
    Eric Mayoux
    Roger Hajjar
    Djamel Lebeche
    Cardiovascular Drugs and Therapy, 2017, 31 : 233 - 246
  • [37] Association Between Cardiorespiratory Fitness and Risk of Type 2 Diabetes: A Meta-Analysis
    Qiu, Shanhu
    Cai, Xue
    Yang, Bingquan
    Du, Ziwei
    Cai, Min
    Sun, Zilin
    Zuegel, Martina
    Steinacker, Juergen Michael
    Schumann, Uwe
    OBESITY, 2019, 27 (02) : 315 - 324
  • [38] Type 2 Diabetes in Youth: A Phenotype of Low Cardiorespiratory Fitness and Reduced Physical Activity
    Shaibi, Gabriel Q.
    Fleet, Sara B.
    Fritschi, Cynthia J.
    Quinn, Lauretta
    Faulkner, Melissa S.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2008, 40 (05): : S21 - S21
  • [39] MARKERS OF GUT LEAKAGE RELATED TO CARDIORESPIRATORY FITNESS IN PATIENTS WITH CAD AND TYPE 2 DIABETES
    Aune, S. K.
    Byrkjeland, R.
    Solheim, S.
    Arnesen, H.
    Troseid, M.
    Seljeflot, I.
    Helseth, R.
    ATHEROSCLEROSIS, 2020, 315 : E59 - E59
  • [40] Cardiorespiratory Fitness, Preclinical Systolic and Diastolic Dysfunctions and HRQoL in Men with Type 2 Diabetes
    Cugusi, Lucia
    Deidda, Martino
    Nocco, Silvio
    Orru, Fabio
    Demuru, Paola
    Caria, Alessandra
    Cabras, Sergio
    Cadeddu, Christian
    Bandino, Stefano
    Massidda, Myosotis
    Mercuro, Giuseppe
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2012, 44 : 236 - 236